Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
Sagimet Biosciences Presents Clinical Denifanstat And Preclinical FASN Inhibitor Data At AASLD The Liver Meeting 2024
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients
FASCINATE-2 2 期試驗的子集分析表明，denifanstat 改善了難以治療的 MASH 患者的纖維化
Both artificial intelligence (AI) and conventional pathology demonstrated denifanstat's strong anti-fibrotic activity
人工智能（AI）和傳統病理學都顯示出denifanstat具有很強的抗纖維化活性
FASN inhibitor treatment reduced atherosclerosis development in mouse model of dyslipidemia and MASH
FASN 抑制劑治療可減少血脂異常和 MASH 小鼠模型中的動脈粥樣硬化發展
SAN MATEO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the presentation of Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor denifanstat, and preclinical data demonstrating potential benefit of FASN inhibition in atherosclerosis, at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, November 15-19, 2024 in San Diego, California.
加利福尼亞州聖馬特奧，2024年11月18日（GLOBE NEWSWIRE）——Sagimet Biosciences Inc.（（薩吉美特，納斯達克股票代碼：SGMT）是一家臨床階段的生物製藥公司，開發針對功能失調的代謝和纖維化通路的新療法，今天宣佈發佈20期數據，證明其脂肪酸合酶（FASN）抑制劑丹尼法尼法的抗纖維化活性在美國肝病研究協會（AASLD）-2024年肝臟會議上，統計數據和臨床前數據表明FASN抑制對動脈粥樣硬化具有潛在益處，2024 年 11 月 15 日至 19 日在加利福尼亞州聖地亞哥舉行。
